A fast-progressing orthotopic ovarian cancer model reveals synergistic antitumor effects of AXL-targeting nanobodies and olaparib
Leveraging the synergistic effects of AXL-Fc with Olaparib, we propose a new AXL-targeting treatment approach for OC that warrants further investigation.
Authors
- Éva Hadadi (ORCID: https://orcid.org/0000-0002-5253-814X)
- Yvon Elkrim (ORCID: https://orcid.org/0000-0003-1432-456X)
- Yani Berckmans (ORCID: https://orcid.org/0000-0003-1350-5596)
- Ayla Debraekeleer (ORCID: https://orcid.org/0000-0002-3109-9862)
- Kim De Veirman (ORCID: https://orcid.org/0000-0002-1313-6121)
- An Coosemans (ORCID: https://orcid.org/0000-0002-7321-4339)
- Damya Laoui (ORCID: https://orcid.org/0000-0002-3373-1403)
- Garcia Patricia Cabrera
- A. Aarushi
- Alícia Gordún Peiró (ORCID: https://orcid.org/0000-0001-7286-9846)
Institutions
- Vrije Universiteit Brussel (BE)
- Rega Institute for Medical Research (BE)
- VIB-KU Leuven Center for Cancer Biology (BE)
- Universitair Ziekenhuis Brussel (BE)
- VIB-UGent Center for Inflammation Research (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1016/j.gore.2025.101998
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00